ArticleMetabolic brain disease2025
Integrative behavioral, histological, and proteomics profiling identifies cerebellar drivers of motor dysfunction in a rat model of hepatic encephalopathy.
Article in Metabolic brain disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neuroprotective Potential of Encapsulated Pomegranate Peel Polyphenols in Doxorubicin- Induced Neurotoxicity.Plant foods for human nutrition (Dordrecht, Netherlands) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Hepatic encephalopathy (HE) is a neuropsychiatric disease caused by liver failure and/or portosystemic shunting and is characterized by cognitive and motor impairments. Although it is typically thought to be reversible after liver transplantation, recent research suggests the opposite. This underscores the need for a deeper understanding of HE pathophysiology. Both motor and cognitive function impairments are characteristic of HE and these two functions are controlled by the cerebellum. Therefore, we performed behavioral and histological studies to investigate motor dysfunction and neurodegeneration in thioacetamide-induced moderate-grade hepatic encephalopathy (MoHE) rats. To further investigate the molecular changes in the cerebellum, we utilized label-free-based mass spectrometry analysis. Rotarod and gait tests indicated gross and fine motor impairment, respectively. Histological examination revealed Purkinje neuron degeneration and Bergmann glial fiber hypertrophy. Mass spectrometry analysis identified 2,002 proteins, of which 65 were significantly differentially expressed (35 upregulated and 30 downregulated). Bioinformatic analysis of these 65 proteins revealed dysregulation of calcium ion signalling, GTPase cycles, endocytosis, and apoptosis. Western blotting showed the upregulation of RheB, MPPCB, and fetuin-A, which further validated the MS results. Immunofluorescence also validated the overexpression of these proteins, along with lactadherin, and showed spatial distribution in the granular and Purkinje layers of the cerebellum. This study provides a profile of proteomic changes in the cerebellum and the associated dysregulated biological pathways that may be responsible for the pathophysiology. These findings not only highlight promising new therapeutic targets but also open the door to the development of innovative treatments that could significantly improve patient outcomes.
Indexed as
Identifiers
41455053What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.